As of 2024-09-19, the Relative Valuation of Ultragenyx Pharmaceutical Inc (RARE) is (273.91) USD. This relative valuation is based on P/E multiples. With the latest stock price at 57.70 USD, the upside of Ultragenyx Pharmaceutical Inc based on Relative Valuation is -574.7%.
The range of the Relative Valuation is (363.09) - (196.78) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 57.2x - 59.3x | 58.2x |
| Forward P/E multiples | 25.1x - 31.0x | 28.0x |
| Fair Price | (363.09) - (196.78) | (273.91) |
| Upside | -729.3% - -441.0% | -574.7% |
| Date | P/E |
| 2024-09-18 | -9.09 |
| 2024-09-17 | -9.21 |
| 2024-09-16 | -9.35 |
| 2024-09-13 | -9.25 |
| 2024-09-12 | -9.11 |
| 2024-09-11 | -8.87 |
| 2024-09-10 | -8.78 |
| 2024-09-09 | -8.79 |
| 2024-09-06 | -8.70 |
| 2024-09-05 | -8.89 |
| 2024-09-04 | -8.84 |
| 2024-09-03 | -8.78 |
| 2024-08-30 | -8.94 |
| 2024-08-29 | -8.97 |
| 2024-08-28 | -9.10 |
| 2024-08-27 | -9.08 |
| 2024-08-26 | -8.99 |
| 2024-08-23 | -8.94 |
| 2024-08-22 | -8.88 |
| 2024-08-21 | -8.99 |
| 2024-08-20 | -8.35 |
| 2024-08-19 | -8.47 |
| 2024-08-16 | -8.36 |
| 2024-08-15 | -8.15 |
| 2024-08-14 | -8.15 |
| 2024-08-13 | -8.16 |
| 2024-08-12 | -8.02 |
| 2024-08-09 | -7.88 |
| 2024-08-08 | -7.92 |
| 2024-08-07 | -7.71 |
| 2024-08-06 | -7.84 |
| 2024-08-05 | -7.73 |
| 2024-08-02 | -7.95 |
| 2024-08-01 | -6.96 |
| 2024-07-31 | -7.09 |
| 2024-07-30 | -7.04 |
| 2024-07-29 | -7.13 |
| 2024-07-26 | -7.07 |
| 2024-07-25 | -7.10 |
| 2024-07-24 | -7.11 |
| 2024-07-23 | -7.12 |
| 2024-07-22 | -7.00 |
| 2024-07-19 | -6.70 |
| 2024-07-18 | -6.74 |
| 2024-07-17 | -6.91 |
| 2024-07-16 | -7.13 |
| 2024-07-15 | -7.00 |
| 2024-07-12 | -7.11 |
| 2024-07-11 | -6.91 |
| 2024-07-10 | -6.69 |